The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Abstract Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients wit...

Full description

Bibliographic Details
Main Authors: Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst
Format: Article
Language:English
Published: BMJ Publishing Group 2018-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer immunotherapy
Consensus statement
Lung cancer
Non-small cell lung cancer
Guideline
Online Access:http://link.springer.com/article/10.1186/s40425-018-0382-2

Internet

http://link.springer.com/article/10.1186/s40425-018-0382-2

Similar Items